Preclinical evaluation of 131I-Bevacizumab — A prospective agent for radioimmunotherapy in VEGF expressing cancers

Simple item page
dc.contributor.authorKameswaran, M.
dc.contributor.authorSarma, H. D.
dc.contributor.authorDash, A.
dc.date.accessioned2017-09-05T09:58:34Z
dc.date.available2017-09-05T09:58:34Z
dc.date.issued2017
dc.description.divisionRPhD;RB&HSDen
dc.format.extent3879 bytes
dc.format.mimetypetext/html
dc.identifier.sourceApplied Radiation and Isotopes, 2017. Vol. 123: pp. 109-113en
dc.identifier.urihttp://hdl.handle.net/123456789/14843
dc.language.isoenen
dc.subjectPreclinical evaluationen
dc.subject131I-Bevacizumaben
dc.subjectradioimmunotherapyen
dc.subjectVEGF expressing canceren
dc.titlePreclinical evaluation of 131I-Bevacizumab — A prospective agent for radioimmunotherapy in VEGF expressing cancersen
dc.typeArticleen

Click here to download

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
0119.htm
Size:
3.79 KB
Format:
Hypertext Markup Language
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.81 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

2017